Please try another search
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Name | Age | Since | Title |
---|---|---|---|
Franck Mouthon | - | 2017 | Co-Founder & Executive Chairman |
Sebastien Descarpentries | - | 2017 | Director |
Julien Veys | - | 2016 | Chief Business Officer & Director |
Jerome Martinez | 62 | 2018 | Independent Director |
Rodolphe Besserve | 51 | 2018 | Independent Director |
Eric Doulat | - | 2021 | Independent Director |
Didier Cussac | - | - | Member of Scientific Council |
Mathieu Charvériat | - | 2017 | Co-Founder, CEO & Director |
Paul Moser | - | - | Member of Scientific Council |
Jean-Antoine Girault | - | - | Member of Scientific Council |
Philippe Marin | - | - | Member of Scientific Council |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review